Strategic Partnership Bigfoot Biomedical is integrating with Abbott’s ecosystem and has existing collaboration history, presenting a clear sales opportunity to offer connected insulin dosing solutions alongside Abbott’s CGM and devices, expanding channel reach and leveraging Abbott's distribution network.

subscription Model The company plans a first-of-its-kind monthly subscription service for smart insulin dosing, creating a recurring revenue channel. This opens upsell opportunities for related clinical services, premium monitoring plans, and device upgrades with ongoing customer engagement.

Integrated Platform Unity platform combines pump and pen modalities with a smartphone app and machine learning, enabling cross-sell of complementary devices, data analytics services, and remote monitoring solutions to endocrinology clinics and diabetes programs.

FDA Cleared Footprint With FDA clearance and prior market launch activity, there is credibility to approach payer programs, patient access initiatives, and hospital systems pursuing advanced AID technologies to reduce complications and improve outcomes.

Global Reach Readiness Active engagement in multiple states and a cadence of partnerships suggests readiness to scale with national and international distributors, enabling BD teams to target healthcare systems, DTC channels, and diabetes care retailers seeking intelligent dosing platforms.